Tenax Therapeutics, Inc. TENX

TENX Company Overview

Tenax Therapeutics, Inc. is a U.S.-based specialty pharmaceutical company focused on developing therapies for cardiopulmonary and pulmonary vascular diseases with significant unmet medical need. The company operates within the biopharmaceutical and cardiovascular therapeutics industries and is publicly traded on the NASDAQ under the ticker TENX. Its strategy centers on advancing late-stage or clinically validated compounds for niche indications where targeted therapies may offer differentiated clinical benefit.

The company’s primary value driver is its lead product candidate TNX-103 (levosimendan), which is being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH‑HFpEF). Levosimendan is a calcium sensitizer and potassium channel opener with prior clinical use outside the United States, giving Tenax a development program based on an established pharmacologic profile. Tenax Therapeutics evolved from earlier corporate entities and rebranded to its current name to reflect a strategic refocus on cardiopulmonary therapeutics rather than broader biotechnology applications.